Skip to main content
. 2021 Mar 12;21(5):481. doi: 10.3892/etm.2021.9912

Figure 3.

Figure 3

IRF2BP2 attenuates inflammation and EMT via KLF2. (A) The interaction between IRF2BP2 and KLF2 was confirmed using a Co-IP assay. (B) HUVECs were transfected with scrambled siRNA, siKLF2#1 or siKLF2#2. The mRNA expression levels of KLF2 were measured using reverse transcription-quantitative PCR analysis. ***P<0.001 vs. the scramble group. (C) The protein expression levels of KLF2 were evaluated using western blot analysis. **P<0.01, ***P<0.001 vs. the scrambled group. (D) The cell viability in different groups was determined using a CCK-8 assay. (E) The levels of TNF-α, IL-1β and IL-6 in the culture medium were assessed using ELISA kits. (F) The protein expression levels of VE-cadherin and vimentin were evaluated using western blot analysis. ***P<0.001 vs. the control group; ##P<0.05, ###P<0.001 vs. the ox-LDL group; ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 vs. the ox-LDL + IRF2BP2 + scramble group. IRF2BP2, interferon regulatory factor binding protein 2; KLF2, Krüppel-like factor 2; EMT, endothelial-to-mesenchymal transition; HUVECs, human umbilical vein endothelial cells; siRNA, small interfering RNA; TNF-α, tumor necrosis factor α; IL-1β, interleukin 1β; ox-LDL, oxidized low-density lipoprotein; Co-IP, co-immunoprecipitation.